Clinical trial Recruiting at 2 sites Interventional Ages 18 to 70

Evaluating CO2 Reactivity to Predict Response to Exposure Therapy for Anxiety Disorders

Official title: Carbon Dioxide (CO2) Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy

Run by University of Texas at Austin · NCT05467683 · Data updated 2026-11-12

This study is testing whether measuring how people react to CO2 can help predict if adults with anxiety disorders will benefit from exposure therapy.

Quick facts

Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment600 (estimated)
SponsorUniversity of Texas at Austin
Academic / other
Locations2 sites (Boston, Massachusetts and 1 other locations)
StatusRecruiting
StartedNovember 2, 2022
Main results expectedDecember 1, 2026
Study endsFebruary 28, 2027
Registry record updatedJune 10, 2026
Trial IDNCT05467683 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are adults aged 18 to 70 with a primary diagnosis of panic disorder, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder.

Probably not a fit

Patients with a history of bipolar or psychotic disorders, substance use disorders, serious cognitive impairment, or active suicidal ideation may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the predictive power of a CO2 challenge as a biomarker for determining the effectiveness of exposure-based therapy in adults with anxiety-related disorders. By evaluating CO2 reactivity in 600 participants diagnosed with conditions such as PTSD, OCD, and various anxiety disorders, the researchers hope to identify those who are likely to benefit from this therapy. The study will incorporate CO2 reactivity into a multivariable model alongside other factors to enhance treatment decision-making. This approach builds on previous research linking orexin system activity to fear extinction deficits.

Why it matters

Potential benefit: If successful, this study could provide a valuable tool for clinicians to better select patients who will respond to exposure-based therapy, potentially reducing suffering and improving treatment outcomes.

How similar studies have gone: While the approach of using CO2 reactivity as a biomarker is innovative, similar studies have shown promise in linking physiological responses to treatment outcomes, suggesting potential for success.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* A primary DSM-5 diagnosis of panic disorder (with or without an agoraphobia diagnosis), social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder as assessed by the Structured Clinical Interview for the DSM-5 (SCID-5)
* A score of 8 or greater on the Overall Anxiety Severity and Impairment Scale (OASIS)
* Ages 18 to 70
* Willingness and ability to provide informed consent and comply with the requirements of the study protocol.
* Proficiency in English (because assessment instruments have only been validated in English)

Exclusion Criteria:

* A lifetime history of bipolar or psychotic disorders, substance use disorders (other than nicotine) or eating disorder in the past 6 months; serious cognitive impairment.
* Active suicidal ideation with at least some intent to act with or without specific plan (a rating of 4 for suicidal ideation on the Columbia-Suicide Severity Rating Scale) or suicidal behaviors (actual attempt, interrupted attempt, aborted or self-interrupted attempt, or preparatory acts or behavior) within the past 6 months.
* Medical conditions contraindicating CO2 inhalation or hyperventilation challenge (e.g., cardiac arrhythmia, cardiac failure, asthma, lung fibrosis, high blood pressure, epilepsy, or stroke).
* Pregnancy or lactation
* Ongoing psychotherapy directed toward the primary disorder.
* Pharmacological treatment started within 8 weeks prior to the screen (patients "stable" on their medication regimen will be included and their medication status will be included as a variable in the model)

Where it's running

  • Boston University
    Boston, Massachusetts, United States
    Recruiting
  • The University of Texas at Austin
    Austin, Texas, United States
    Recruiting

Study contacts

  • Principal investigator: Jasper Smits, Ph.D. — The University of Texas at Austin

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.